Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
Key facts
- Who runs it
- Corewell Health East
- Trial code
- Status
- Withdrawn
- Started
- Jun 2023
- Ended
- Jun 2024
- Type of study
- Interventional
- Treatments tested
- CTA/FFRct
- SOC cardiovascular evaluation
- Record updated
- 2 March 2023
- Why it stopped
- Essential staff for study execution left the institution and no suitable replacement could be found.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with end-stage liver disease
- Patients undergoing cardiovascular risk assessment prior to liver transplantation -
Who cannot take part
- Heart rate > 90 bpm despite beta blocker therapy
- Estimated Glomerular Filtration Rate (eGFR) < 30 cc/min/1.73 m\^2 (unless patient is on dialysis or renal transplant is planned)
- Body Mass Index (BMI) > 40 plus chest obesity (i.e. truncal obesity and normal chest morphology is not an exclusion)
- Pregnant Women
About the trial
What the trial wants to find out
Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease. Consultation with cardiologist and stress tests are recommended to patients under consideration for liver transplant. The purpose of this study is to evaluate if Computed Tomography Angiogram (CTA) and CTA-derived Fractional Flow Reserve (FFRct) procedure influences decisions about further cardiac testing compared with Standard of Care (SOC) such as consultation by a cardiologist, Echocardiogram (ultrasound of the heart), Electrocardiogram (ECG) and stress tests.
The group in the trial
- Evaluation of Standard of care followed by CTA/FFRctTreatment being tested
Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
Treatment: CTA/FFRct and SOC cardiovascular evaluation
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct in Patients With End-Stage Liver Disease Under Consideration for Liver Transplant.
- Record updated
- 2 March 2023